Literature DB >> 11129787

Contrast agent specific imaging modes for the ultrasonic assessment of parenchymal cerebral echo contrast enhancement.

T Postert1, P Hoppe, J Federlein, S Helbeck, H Ermert, H Przuntek, T Büttner, W Wilkening.   

Abstract

Previous work has demonstrated that cerebral echo contrast enhancement can be assessed by means of transcranial ultrasound using transient response second harmonic imaging (HI). The current study was designed to explore possible advantages of two new contrast agent specific imaging modes, contrast burst imaging (CBI) and time variance imaging (TVI), that are based on the detection of destruction or splitting of microbubbles caused by ultrasound in comparison with contrast harmonic imaging (CHI), which is a broadband phase-inversion-based implementation of HI. Nine healthy individuals with adequate acoustic temporal bone windows were included in the study. Contrast harmonic imaging, CBI, and TVI examinations were performed in an axial diencephalic plane of section after an intravenous bolus injection of 4 g galactose-based microbubble suspension in a concentration of 400 mg/mL. Using time-intensity curves, peak intensities and times-to peak-intensity (TPIs) were calculated off-line in anterior and posterior parts of the thalamus, in the region of the lentiform nucleus, and in the white matter. The potential of the different techniques to visualize cerebral contrast enhancement in different brain areas was compared. All techniques produced accurate cerebral contrast enhancement in the majority of investigated brain areas. Contrast harmonic imaging visualized signal increase in 28 of 36 regions of interest (ROIs). In comparison, TVI and CBI examinations were successful in 32 and 35 investigations, respectively. In CHI examinations, contrast enhancement was most difficult to visualize in posterior parts of the thalamus (6 of 9) and the lentiform nucleus (6 of 9). In TVI examinations, anterior parts of the thalamus showed signal increase in only 6 of 9 examinations. For all investigated imaging modes, PIs and TPIs in different ROIs did not differ significantly, except that TVI demonstrated significantly higher PIs in the lentiform nucleus as compared with the thalamus and the white matter (P < 0.05). The current study demonstrates for the first time that CBI and TVI represent new ultrasonic tools that allow noninvasive assessment of focal cerebral contrast enhancement and that CBI and TVI improve diagnostic sensitivity as compared with CHI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129787     DOI: 10.1097/00004647-200012000-00010

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  5 in total

1.  Microbubbles traversing the blood-brain barrier for imaging and therapy.

Authors:  Stephen Meairs; Angelika Alonso; Marc Fatar; Rolf Kern; Michael Hennerici
Journal:  Med Biol Eng Comput       Date:  2009-03-13       Impact factor: 2.602

2.  Pitch-catch phase aberration correction of multiple isoplanatic patches for 3-D transcranial ultrasound imaging.

Authors:  Brooks D Lindsey; Stephen W Smith
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2013-03       Impact factor: 2.725

3.  Detecting stripe artifacts in ultrasound images.

Authors:  Adam Maciak; Christian Kier; Günter Seidel; Karsten Meyer-Wiethe; Ulrich G Hofmann
Journal:  J Digit Imaging       Date:  2007-07-25       Impact factor: 4.056

4.  Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Pei-Li Fan; Yu-Quan Xiong; Peng-Yuan Zhuang; Wei Zhang; Hua-Xiang Xu; Dong-Mei Gao; Ling-Qun Kong; Lu Wang; Wei-Zhong Wu; Zhao-You Tang; Hong Ding; Hui-Chuan Sun
Journal:  BMC Cancer       Date:  2011-01-20       Impact factor: 4.430

Review 5.  Twenty Years of Cerebral Ultrasound Perfusion Imaging-Is the Best yet to Come?

Authors:  Jens Eyding; Christian Fung; Wolf-Dirk Niesen; Christos Krogias
Journal:  J Clin Med       Date:  2020-03-17       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.